NEWTON, Mass., Oct. 26, 2020 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that it
will report third quarter 2020 financial results on Monday, November 2, 2020. Karyopharm's management
team will host a conference call and audio webcast at 4:30 p.m. ET
on Monday, November 2, 2020, to
discuss the financial results and other company updates.
To access the conference call, please dial (877) 870-4263
(local) or (412) 317-0790 (international) at least 10
minutes prior to the start time and ask to be joined into the
Karyopharm Therapeutics call. A live audio webcast of the call will
be available under "Events & Presentations" in the
Investor section of the Company's
website, http://investors.karyopharm.com/events-presentations.
An archived webcast will be available on the Company's website
approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies and dedicated to the discovery, development, and
commercialization of novel first-in-class drugs directed against
nuclear export and related targets for the treatment of cancer and
other major diseases. Karyopharm's Selective Inhibitor of Nuclear
Export (SINE) compounds function by binding with and inhibiting the
nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound,
XPOVIO® (selinexor), received accelerated approval from the U.S.
Food and Drug Administration (FDA) in July
2019 in combination with dexamethasone as a treatment for
patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a
treatment for patients with relapsed or refractory diffuse large
B-cell lymphoma. A Marketing Authorization Application for
selinexor for patients with heavily pretreated multiple myeloma is
also currently under review by the European Medicines Agency. In
addition to single-agent and combination activity against a variety
of human cancers, SINE compounds have also shown biological
activity in models of neurodegeneration, inflammation, autoimmune
disease, certain viruses and wound-healing. Karyopharm has several
investigational programs in clinical or preclinical development.
For more information, please visit www.karyopharm.com.
View original
content:http://www.prnewswire.com/news-releases/karyopharm-to-report-third-quarter-2020-financial-results-on-november-2-2020-301159231.html
SOURCE Karyopharm Therapeutics Inc.